Efficacy and Safety of Autologous Cytokine-Induced Killer (CIK) Cellular Immunotherapy Combined with Chemotherapy in Non-Small-Cell Carcinoma (NSCLC): A Meta-Analysis
Abstract
Background: To investigate the efficacy and safety of autologous Cytokine-induced killer (CIK) cellular immunotherapy combined with chemotherapy for non-small-cell carcinoma (NSCLC).
Methods: The literature related to the efficacy and safety of autologous CIK cellular immunotherapy combined with chemotherapy in NSCLC were collected. The Chinese literature databases were collected from CNKI, Wanfang and Weipu, and the English literature were retrieved from Cochrane Library and PubMed. All literature were retrieved until the year of 2022, and evaluated by its method quality and analyzed by RevMan5.3 software.
Results: A Meta-analysis on the 11 included literature showed that the treatment efficacy and disease control rate (DCR) of patients in the observation group were significantly higher than those in the control group (P＜0.05), and significantly increased the levels of CD3+, CD4+, CD4+/CD8+ indexes than the control group (P＜0.05), and the incidence of bone marrow suppression, liver injury and gastrointestinal symptoms were significantly lower than those of the control group (P＜0.05).
Conclusion: Compared with single chemotherapy, CIK combined with chemotherapy in the treatment of patients with NSCLC can improve the efficacy of treatment and DCR, significantly improve their immune function, reduce the incidence of adverse reactions, and is beneficial to the recovery of prognosis.
2. Duma N, Santana-Davila R, Molina JR (2019). Non-Small Cell Lung Cancer: Ep-idemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc, 94(8):1623-1640.
3. Reck M, Remon J, Hellmann M D (2022). First-line immunotherapy for non–small-cell lung cancer. J Clin Oncol, 40(6):586-597.
4. Chen J, Chen Y, Feng F, et al (2018). Non-small cell lung cancer (NSCLC)% cyto-kine-induced killer (CIK)% natural killer (NK)% programmed cell death protein-1 (PD-1)% programmed death-ligand 1 (PD-L1). J Thorac Dis, 10(12):6711-6721.
5. Zhang J, Li H, Gao D, et al (2018). A prog-nosis and impact factor analysis of DC-CIK cell therapy for patients with hepa-tocellular carcinoma undergoing post-operative TACE. Cancer Biol Ther, 19(6):475-483.
6. He Y, Guo X, May BH, et al (2020). Clinical Evidence for Association of Acupunc-ture and Acupressure with Improved Cancer Pain: A Systematic Review and Meta-Analysis. JAMA Oncol, 6(2):271-278.
7. Ye Ruiping, Cai Shuhua, Liu Bo, et al (2016). Observations on the efficacy of CIK cells combined with chemotherapy in advanced non-small cell lung cancer. J Clin Pulmonol, 21(8):1489-1492.
8. WANG Xiuwen, YI Jiqun, LIANG Jizhen, et al (2017). Analysis of the efficacy of CIK cells on maintenance therapy for advanced non-small cell lung cancer af-ter first-line chemotherapy. Journal of Practical Cancer, 32(3):473-476.
9. He Xiaoyuan, Xiao Xia, Li Qing, et al (2019). Anti-CD19 CAR-T as a feasible and safe treatment against central nerv-ous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL. Leukemia, 33, 2102-2104.
10. LI Jie, YANG Rongyue, LI Fuguang (2015). CIK cellular immunotherapy in inter-mediate and advanced non-small cell lung cancer. International Medical and Health Herald, 21(18):2663-2665.
11. LI Lei, ZHONG Minyu, GUO Peizhong, et al (2016). Chemotherapy combined with CIK cell immunotherapy for small cell lung cancer. Modern Oncology Medicine, 24(15):2406-2409.
12. YANG Jia, KWONG Xiankui, JI Liping, et al (2015). Observation on the efficacy of chemotherapy combined with autolo-gous CIK cell immunotherapy for ad-vanced non-small cell lung cancer. Chi-nese Journal of Practical Diagnosis and Thera-py, 29(1):31-33.
13. WANG Jinshuo, XIE Zexin, LI Huijie, et al (2015). Observation on the efficacy of autologous CIK cells combined with chemotherapy for second-line treatment of advanced non-small cell lung cancer. Hebei Medicine, 2015(10):1477-1479.
14. DU Guowei, WANG Wenming, PENG Zongyu, et al (2016). Clinical effect study of autologous CIK cells combined with pemetrexed and cisplatin in the treat-ment of non-small cell lung cancer. In-ternational Respiratory Journal, 36(18):1376-1379.
15. DING Zhenyu, HAN Yaling, PARK Ying, et al (2015). Efficacy and safety of au-tologous CIK cells combined with chemotherapy for first-line mainte-nance treatment of non-small cell lung cancer. Journal of PLA Medicine, 2015(1):31-36,40.
16. HAN Lige, LIU Jingchun (2021). Clinical effects of cytokine-induced killer cell immunization combined with TP regi-men in the treatment of non-small cell lung cancer. Henan Medical Research, 30(6):1023-1026.
17. Meng Xianlu (2020). Observation on the ef-ficacy of DP combined with CIK in the treatment of advanced non-small cell carcinoma. Tibetan Medicine, 41(06):70-71.
18. CHEN Yu-Hong, YANG Biao (2022). Im-munotherapy-related biomarkers in di-gestive tract tumors. China Cancer Clinic, 49(12):631-635.
19. Li SJ, Zhang LS, Chai Y, Zhang YF, Zhang YM, Zeng PY, Wu CY (2007). [Killing ac-tivity of co-cultured cytokine-induced killer cells and dendritic cells against multi-drug resistant tumor cell lines]. Zhonghua Zhong Liu Za Zhi, 29(10):733-7.
20. Engels EA (2019). Epidemiologic perspec-tives on immunosuppressed populations and the immunosurveillance and im-munocontainment of cancer. Am J Transplant, 19(12):3223-3232.
21. Huang M, Wang X, Bin H (2015). Effect of Transcatheter Arterial Chemoemboliza-tion Combined with Argon-Helium Cry-osurgery System on the Changes of NK Cells and T Cell Subsets in Peripheral Blood of Hepatocellular Carcinoma Pa-tients. Cell Biochem Biophys, 73(3):787-92.
22. Li X, Dai D, Song X, et al (2014). A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol, 38(5): 583-591.
23. Trushina EN, Mustafina OK, Aksenov IV, Krasutsky AG, Nikityuk DB, Tutelyan VA (2023). [Bioactive compounds antho-cyanins as a factor in the nutritional re-covery of the body's adaptive potential after intense physical activity in the ex-periment: assessment of immunological and hematological indicators of adapta-tion]. Vopr Pitan, 92(1):6-15.
| Files | ||
| Issue | Vol 53 No 8 (2024) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v53i8.16277 | |
| Keywords | ||
| CIK cellular immunity Chemotherapy Curative effect Security Meta-analysis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
